celecoxib has been researched along with Carcinoma, Small Cell in 4 studies
Carcinoma, Small Cell: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Edelman, MJ | 1 |
| Wang, X | 1 |
| Hodgson, L | 1 |
| Cheney, RT | 1 |
| Baggstrom, MQ | 1 |
| Thomas, SP | 1 |
| Gajra, A | 1 |
| Bertino, E | 1 |
| Reckamp, KL | 1 |
| Molina, J | 1 |
| Schiller, JH | 1 |
| Mitchell-Richards, K | 1 |
| Friedman, PN | 1 |
| Ritter, J | 1 |
| Milne, G | 1 |
| Hahn, OM | 1 |
| Stinchcombe, TE | 1 |
| Vokes, EE | 1 |
| Natale, RB | 1 |
| Blackhall, F | 1 |
| Papakotoulas, PI | 1 |
| Danson, S | 1 |
| Thatcher, N | 1 |
| Kanwar, VS | 1 |
| Heath, J | 1 |
| Krasner, CN | 1 |
| Pearce, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer[NCT01041781] | Phase 3 | 313 participants (Actual) | Interventional | 2010-02-28 | Terminated (stopped due to DSMB recommendation) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment (NCT01041781)
Timeframe: Up to 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Arm I (Arm A: Celecoxib + Standard Chemotherapy) | 61.04 |
| Arm II (Arm B: Placebo + Standard Chemotherapy) | 55.06 |
Overall survival time is defined as the time from randomization to death due to any cause. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT01041781)
Timeframe: Time between randomization and death from any cause, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| Arm I (Arm A: Celecoxib + Standard Chemotherapy) | 11.4 |
| Arm II (Arm B: Placebo + Standard Chemotherapy) | 12.5 |
Prognostic value of urinary prostaglandin metabolites (PGE-M) levels for worse PFS for patients who had baseline urinary PGE-M above/below the first quartile (Q1, 10.09). Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT01041781)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| PGE-M < Q1 | 7.7 |
| PGE-M >= Q1 | 4.9 |
prognostic value of urinary prostaglandin metabolites (PGE-M) levels for worse PFS for patients who had baseline urinary PGE-M above/below the median quartile (Q2, 15.38). Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT01041781)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| PGE-M < Q2 | 6.2 |
| PGE-M >= Q2 | 4.2 |
Prognostic value of urinary prostaglandin metabolites (PGE-M) levels for worse PFS for patients who had baseline urinary PGE-M above/below the median quartile (Q3, 27.86). Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT01041781)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| PGE-M < Q3 | 6.0 |
| PGE-M >= Q3 | 3.0 |
Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT01041781)
Timeframe: Time between randomization and disease relapse or death from any cause, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| Arm I (Arm A: Celecoxib + Standard Chemotherapy) | 5.16 |
| Arm II (Arm B: Placebo + Standard Chemotherapy) | 5.26 |
The response rate (percentage) is the percent of patients whose best response was Complete Response (CR) or Partial Response (PR) as defined by RECIST 1.1 criteria. Percentage of successes will be estimated by 100 times the number of successes divided by the total number of evaluable patients. Response rates (including complete and partial response) will be tested using Fisher's exact test (NCT01041781)
Timeframe: Up to 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Arm I (Arm A: Celecoxib + Standard Chemotherapy) | 40 |
| Arm II (Arm B: Placebo + Standard Chemotherapy) | 35 |
2 reviews available for celecoxib and Carcinoma, Small Cell
| Article | Year |
|---|---|
Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Celecoxib; Cisp | 2003 |
Perspectives on novel therapies for bronchial carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2005 |
1 trial available for celecoxib and Carcinoma, Small Cell
| Article | Year |
|---|---|
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Celecoxib; Cyclo | 2017 |
1 other study available for celecoxib and Carcinoma, Small Cell
| Article | Year |
|---|---|
Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Carcinoma, Small | 2008 |